Meloxicam SBEβCD Inclusion Complex for Rapid Migraine Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility leading to reduced bioavailability and slow onset of pain relief, necessitating a method to enhance its solubility and absorption.
Innovation Solution
The use of a combination of meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and a bicarbonate, forming an inclusion complex to increase solubility and bioavailability, along with rizatriptan for enhanced pain relief in treating migraines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used as a conventional NSAID, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows onset of pain relief
Solution Approach 1:
Cyclodextrins are used as intermediary carriers that form inclusion complexes with meloxicam. The cyclodextrin structure provides a hydrophobic interior cavity that accommodates the meloxicam molecule, while the hydrophilic exterior enables aqueous solubility. This mediator resolves the contradiction by allowing meloxicam to be transported in aqueous environments without compromising its molecular integrity or therapeutic activity.
Solution Approach 2:
The invention changes the physical-chemical parameters of meloxicam by forming an inclusion complex. The complexation alters the solubility parameter of meloxicam from poor to good aqueous solubility, while maintaining the pharmacologically active concentration. This parameter change enables improved bioavailability without altering the fundamental anti-inflammatory and analgesic properties of meloxicam.
2Speed
If meloxicam is administered to achieve therapeutic effect, then anti-inflammatory activity is provided, but the onset of pain relief is slow due to poor solubility
Solution Approach 1:
The cyclodextrin inclusion complex acts as a mediator that accelerates the dissolution and absorption of meloxicam. By providing a pre-solubilized complex, the intermediary eliminates the slow dissolution step that normally precedes absorption, thereby speeding up the onset of pain relief while maintaining the therapeutic anti-inflammatory effect.
Solution Approach 2:
The meloxicam is pre-complexed with cyclodextrin before administration, creating a ready-to-absorb formulation. This preliminary action of complexation ensures that the drug is in a solubilized state upon administration, eliminating the delay associated with dissolution and enabling faster onset of analgesic effect.
3Reliability
If conventional NSAID formulations are used, then treatment is provided, but inadequate response is observed in patients with history of poor response to prior treatments
Solution Approach 1:
The invention changes the delivery parameter of meloxicam from conventional solid dosage to cyclodextrin inclusion complex. This parameter change in formulation technology provides a new treatment approach for patients who have inadequate response to conventional NSAID formulations, improving reliability of treatment response in this difficult-to-treat population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases the oral bioavailability of meloxicam, providing rapid and sustained pain relief in migraine patients with a history of inadequate response to prior treatments, reducing the need for rescue medication and offering improved pain freedom and relief compared to meloxicam or rizatriptan alone.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.